Literature DB >> 23581252

Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels.

Y Dargaud1, M Hoffman, L Lefrapper, F-C Lin, A Genty, B Chatard, S Marin, C Négrier, D M Monroe.   

Abstract

OBJECTIVE: Bleeding is the main complication of warfarin therapy, even patients with an international normalized ratio (INR) in the target range can suffer bleeding, suggesting that INR does not perfectly reflect the therapeutic effect of warfarin. We hypothesized the INR might underestimate the level of anticoagulation in a subject with a lower factor (F) IX level than average. METHODS AND
RESULTS: We modeled warfarin anticoagulation in our in vitro thrombin generation (TG) model by adjusting the levels of vitamin K-dependent factors to those of patients with an INR of 2-3. Variation in FIX had a marked effect on TG but had no effect on the prothrombin time (PT)-INR. A prospective observational, cross-sectional clinical study including 341 consecutive patients admitted to the emergency department with an INR between 2 and 3, showed a statistically lower FIX activity in bleeders (P = 0.004) compared with others. No correlation was found between TG capacity and PT-INR results (P = 0.36). However, in patients, presenting with a warfarin-related hemorrhage, TG was significantly lower (P < 0.001) than others. A correlation on the boundary of significance was observed between TG capacity and FIX levels (P = 0.09).
CONCLUSION: These data demonstrates that patients who bleed when their PT-INR is in the target range 2-3 might have defective TG related to a lower level of FIX than expected.
© 2013 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  bleeding and blood coagulation tests; factor IX; international normalized ratio; warfarin

Mesh:

Substances:

Year:  2013        PMID: 23581252     DOI: 10.1111/jth.12244

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  7 in total

Review 1.  Impact of Non-Vitamin K Antagonist Oral Anticoagulants From a Basic Science Perspective.

Authors:  Maureane Hoffman; Dougald M Monroe
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-08-10       Impact factor: 8.311

2.  Prediction of bleeding risk in patients taking vitamin K antagonists using thrombin generation testing.

Authors:  Saartje Bloemen; Suzanne Zwaveling; Hugo Ten Cate; Arina Ten Cate-Hoek; Bas de Laat
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

3.  Thrombin generation in low plasma volumes.

Authors:  Saartje Bloemen; Hilde Kelchtermans; H Coenraad Hemker
Journal:  Thromb J       Date:  2018-05-15

4.  Global assays and the management of oral anticoagulation.

Authors:  Herm Jan M Brinkman
Journal:  Thromb J       Date:  2015-02-10

5.  Supporting the use of a coagulometric method for rivaroxaban control: a hypothesis-generating study to define the safety cut-offs.

Authors:  Raul Altman; Claudio Daniel Gonzalez
Journal:  Thromb J       Date:  2015-08-06

6.  Delayed Thrombin Generation Is Associated with Minor Bleedings in Venous Thromboembolism Patients on Rivaroxaban: Usefulness of Calibrated Automated Thrombography.

Authors:  Jaroslaw Zalewski; Konrad Stepien; Karol Nowak; Sandi Caus; Saulius Butenas; Anetta Undas
Journal:  J Clin Med       Date:  2020-06-27       Impact factor: 4.964

7.  [Monitoring of coagulation by intraoperative thromboelastometry of liver transplantation in a patient using warfarin - case report].

Authors:  José Carlos Rodrigues Nascimento; David Silveira Marinho; Rodrigo Dornfeld Escalante; Bodiyabaduge Emmanuel M Daya Pereira Junior; Cristiane Gurgel Lopes; Rogean Rodrigues Nunes
Journal:  Braz J Anesthesiol       Date:  2018-06-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.